Dr. Johannes Bange is a chemist by training, European Patent Attorney and co‑founder of U3Pharma, where he built and led antibody discovery and development from inception through multiple clinical-stage assets, including four therapeutic antibodies advanced up to phase III trials. As CEO/CSO of U3Pharma and later in global roles at Daiichi Sankyo in Europe and Japan, he led IND readiness, CMC, tox/PK and translational strategies, and helped drive the acquisition of U3Pharma by Daiichi Sankyo.
He brings extensive intercultural leadership experience from operational roles across the US, EU and Japan, managing diverse international teams and collaborations in a global pharma environment. He is currently Partner at Khanu Management GmbH, where he sources and diligences early-stage academic projects for the KHAN Technology Transfer Fund I, combining scientific, IP and financial risk assessment to build value-generating biotech portfolios.
